| Literature DB >> 23303902 |
Malin Pedersen1, Heidi V N Küsters-Vandevelde2, Amaya Viros1, Patricia J T A Groenen3, Berta Sanchez-Laorden1, Jacobus H Gilhuis4, Ilse A van Engen-van Grunsven2, Willy Renier5, Jolanda Schieving6, Ion Niculescu-Duvaz7, Caroline J Springer7, Benno Küsters2, Pieter Wesseling2,3,8, Willeke A M Blokx3, Richard Marais1,9.
Abstract
UNLABELLED: NRAS mutations are common in human melanoma. To produce a mouse model of NRAS-driven melanoma, we expressed oncogenic NRAS (NRAS(G12D)) in mouse melanocytes. When NRAS(G12D) was expressed in the melanocytes of developing embryos, it induced melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue nevi but did not induce cutaneous melanoma. Unexpectedly, however, it did induce early-onset primary melanoma of the central nervous system (CNS). The tumors were rapidly proliferating and caused neurologic symptoms, rapid health deterioration, and death. NRAS is not a common driver oncogene of primary melanoma of the CNS in adults, but we report two cases of primary melanoma of the CNS in children, both of which carried oncogenic mutations in NRAS. We conclude that acquisition of somatic mutations in NRAS in CNS melanocytes is a predisposing risk factor for primary melanoma of the CNS in children, and we present a mouse model of this disease. SIGNIFICANCE: We show that the acquisition of NRAS mutations in melanocytes during embryogenesis is a risk factor for early-onset melanoma of the CNS. We have developed a powerful mouse model to study this rare but devastating childhood disease, and to develop therapeutic approaches for its treatment. ©2013 AACR.Entities:
Mesh:
Year: 2013 PMID: 23303902 PMCID: PMC3999382 DOI: 10.1158/2159-8290.CD-12-0464
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397